Minit Shah

@DrVijayPatil11 @VanitaNoronha @Amolpatel_dr @Nandinimenon18 @DrEzraCohen @JCO_ASCO @HHKhar @TataMemorial @DrHaddadRobert Thank you sir for giving us the answer we wanted in cisplatin ineligible LAHNSCC. We knew Carboplatin was not enough, we couldn't admit all our patients for Carbo-5FU, now we have an effective, safe and cheaper solution!!

Phase III Randomized Trial for Use of Docetaxel in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. @VanitaNoronha @Amolpatel_dr @Nandinimenon18 @DrEzraCohen @JCO_ASCO @HHKhar @TataMemorial @DrHaddadRobert ascopubs.org/doi/abs/10.120…

@NEUROconnectIN @DrVijayPatil11 @VivekSharmaSE Taking Neuro-oncology in India a step ahead, connecting all the patients in a common platform, the 1st ever virtual Neuro-oncology patient support programme was held on 24/11/22 and will be held on the 24th of each month (#24*7)

It indeed was a great start of India’s First neuro-oncology support group program “Neuro Connect” inaugurated and led by Dr. Vijay Patil and moderated by Mr. Sanjeev Sharma. . . . #neuroconnect #braintumor #cnscancers #braincancer #patientsupportgroup

@DrVijayPatil11 @JCO_ASCO @VanitaNoronha @Nandinimenon18 @Amolpatel_dr @SuyogCancer @tmhmedoncalumni @oncology_bg I'm sure this is just the start of a new era! Congratulations Vijay sir!

Very Happy 🎉🎉 to share that low dose immunotherapy full text is published in JCO. @JCO_ASCO @VanitaNoronha @Nandinimenon18 @Amolpatel_dr @SuyogCancer @tmhmedoncalumni @oncology_bg Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study . ascopubs.org/doi/abs/10.120…

Positive and Negative outcomes from clinical trials need to be published. Another landmark from Tata Memorial Hospital Solid Unit 2 department!! Mebendazole plus lomustine or temozolomide in patients with recurrent ... sciencedirect.com/science/articl…

Congratulations TMH - Solid II m.facebook.com/story.php?stor…